ID   KAT2B_HUMAN             Reviewed;         832 AA.
AC   Q92831; Q6NSK1;
DT   19-OCT-2002, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2005, sequence version 3.
DT   10-MAY-2017, entry version 187.
DE   RecName: Full=Histone acetyltransferase KAT2B;
DE            EC=2.3.1.48;
DE   AltName: Full=Histone acetyltransferase PCAF;
DE            Short=Histone acetylase PCAF;
DE   AltName: Full=Lysine acetyltransferase 2B;
DE   AltName: Full=P300/CBP-associated factor;
DE            Short=P/CAF;
GN   Name=KAT2B; Synonyms=PCAF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:AAC50890.2};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, TISSUE SPECIFICITY, AND
RP   INTERACTION WITH EP300 AND CREBBP.
RC   TISSUE=Liver;
RX   PubMed=8684459; DOI=10.1038/382319a0;
RA   Yang X.-J., Ogryzko V.V., Nishikawa J., Howard B.H., Nakatani Y.;
RT   "A p300/CBP-associated factor that competes with the adenoviral
RT   oncoprotein E1A.";
RL   Nature 382:319-324(1996).
RN   [2] {ECO:0000305}
RP   SEQUENCE REVISION.
RC   TISSUE=Liver;
RA   Nakatani Y.;
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   ENZYME ACTIVITY.
RX   PubMed=8945521; DOI=10.1016/S0092-8674(00)82001-2;
RA   Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y.;
RT   "The transcriptional coactivators p300 and CBP are histone
RT   acetyltransferases.";
RL   Cell 87:953-959(1996).
RN   [5]
RP   INTERACTION WITH NCOA3.
RX   PubMed=9346901; DOI=10.1074/jbc.272.44.27629;
RA   Takeshita A., Cardona G.R., Koibuchi N., Suen C.-S., Chin W.W.;
RT   "TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule,
RT   exhibits distinct properties from steroid receptor coactivator-1.";
RL   J. Biol. Chem. 272:27629-27634(1997).
RN   [6]
RP   INTERACTION WITH NCOA1.
RX   PubMed=9296499; DOI=10.1038/38304;
RA   Spencer T.E., Jenster G., Burcin M.M., Allis C.D., Zhou J.,
RA   Mizzen C.A., McKenna N.J., Onate S.A., Tsai S.Y., Tsai M.-J.,
RA   O'Malley B.W.;
RT   "Steroid receptor coactivator-1 is a histone acetyltransferase.";
RL   Nature 389:194-198(1997).
RN   [7]
RP   INTERACTION WITH KLF1, AND FUNCTION.
RX   PubMed=9707565; DOI=10.1073/pnas.95.17.9855;
RA   Zhang W., Bieker J.J.;
RT   "Acetylation and modulation of erythroid Krueppel-like factor (EKLF)
RT   activity by interaction with histone acetyltransferases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9855-9860(1998).
RN   [8]
RP   INTERACTION WITH E2F1, AND FUNCTION.
RX   PubMed=10675335; DOI=10.1093/emboj/19.4.662;
RA   Martinez-Balbas M.A., Bauer U.M., Nielsen S.J., Brehm A.,
RA   Kouzarides T.;
RT   "Regulation of E2F1 activity by acetylation.";
RL   EMBO J. 19:662-671(2000).
RN   [9]
RP   INTERACTION WITH HTLV-1 TAX.
RX   PubMed=10766811; DOI=10.1074/jbc.275.16.11852;
RA   Harrod R., Kuo Y.-L., Tang Y., Yao Y., Vassilev A., Nakatani Y.,
RA   Giam C.-Z.;
RT   "p300 and p300/cAMP-responsive element-binding protein associated
RT   factor interact with human T-cell lymphotropic virus type-1 Tax in a
RT   multi-histone acetyltransferase/activator-enhancer complex.";
RL   J. Biol. Chem. 275:11852-11857(2000).
RN   [10]
RP   INTERACTION WITH MECOM.
RX   PubMed=11568182; DOI=10.1074/jbc.M106733200;
RA   Chakraborty S., Senyuk V., Sitailo S., Chi Y., Nucifora G.;
RT   "Interaction of EVI1 with cAMP-responsive element-binding protein-
RT   binding protein (CBP) and p300/CBP-associated factor (P/CAF) results
RT   in reversible acetylation of EVI1 and in co-localization in nuclear
RT   speckles.";
RL   J. Biol. Chem. 276:44936-44943(2001).
RN   [11]
RP   INTERACTION WITH HIV-1 TAT.
RX   PubMed=12486002; DOI=10.1093/emboj/cdf669;
RA   Bres V., Tagami H., Peloponese J.-M., Loret E., Jeang K.-T.,
RA   Nakatani Y., Emiliani S., Benkirane M., Kiernan R.E.;
RT   "Differential acetylation of Tat coordinates its interaction with the
RT   co-activators cyclin T1 and PCAF.";
RL   EMBO J. 21:6811-6819(2002).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH NPAS2; ARNTL/BMAL1 AND CLOCK.
RX   PubMed=14645221; DOI=10.1074/jbc.M311973200;
RA   Curtis A.M., Seo S.B., Westgate E.J., Rudic R.D., Smyth E.M.,
RA   Chakravarti D., FitzGerald G.A., McNamara P.;
RT   "Histone acetyltransferase-dependent chromatin remodeling and the
RT   vascular clock.";
RL   J. Biol. Chem. 279:7091-7097(2004).
RN   [13]
RP   INTERACTION WITH NFE4.
RX   PubMed=15273251; DOI=10.1074/jbc.M405129200;
RA   Zhao Q., Cumming H., Cerruti L., Cunningham J.M., Jane S.M.;
RT   "Site-specific acetylation of the fetal globin activator NF-E4
RT   prevents its ubiquitination and regulates its interaction with the
RT   histone deacetylase, HDAC1.";
RL   J. Biol. Chem. 279:41477-41486(2004).
RN   [14]
RP   INTERACTION WITH TACC1; TACC2 AND TACC3.
RX   PubMed=14767476; DOI=10.1038/sj.onc.1207424;
RA   Gangisetty O., Lauffart B., Sondarva G.V., Chelsea D.M., Still I.H.;
RT   "The transforming acidic coiled coil proteins interact with nuclear
RT   histone acetyltransferases.";
RL   Oncogene 23:2559-2563(2004).
RN   [15]
RP   INTERACTION WITH NR2C2.
RX   PubMed=16887930; DOI=10.1074/mcp.M600180-MCP200;
RA   Huq M.D., Gupta P., Tsai N.P., Wei L.N.;
RT   "Modulation of testicular receptor 4 activity by mitogen-activated
RT   protein kinase-mediated phosphorylation.";
RL   Mol. Cell. Proteomics 5:2072-2082(2006).
RN   [16]
RP   INTERACTION WITH DDX17.
RX   PubMed=17226766; DOI=10.1002/jcb.21250;
RA   Shin S., Janknecht R.;
RT   "Concerted activation of the Mdm2 promoter by p72 RNA helicase and the
RT   coactivators p300 and P/CAF.";
RL   J. Cell. Biochem. 101:1252-1265(2007).
RN   [17]
RP   INTERACTION WITH CEBPB.
RX   PubMed=17301242; DOI=10.1073/pnas.0607378104;
RA   Wiper-Bergeron N., Salem H.A., Tomlinson J.J., Wu D., Hache R.J.;
RT   "Glucocorticoid-stimulated preadipocyte differentiation is mediated
RT   through acetylation of C/EBPbeta by GCN5.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:2703-2708(2007).
RN   [18]
RP   IDENTIFICATION IN A LARGE CHROMATIN REMODELING COMPLEX.
RX   PubMed=17707232; DOI=10.1016/j.molcel.2007.07.024;
RA   Zhu P., Zhou W., Wang J., Puc J., Ohgi K.A., Erdjument-Bromage H.,
RA   Tempst P., Glass C.K., Rosenfeld M.G.;
RT   "A histone H2A deubiquitinase complex coordinating histone acetylation
RT   and H1 dissociation in transcriptional regulation.";
RL   Mol. Cell 27:609-621(2007).
RN   [19]
RP   INTERACTION WITH BCAS3.
RX   PubMed=17505058; DOI=10.1210/me.2006-0514;
RA   Gururaj A.E., Peng S., Vadlamudi R.K., Kumar R.;
RT   "Estrogen induces expression of BCAS3, a novel estrogen receptor-alpha
RT   coactivator, through proline-, glutamic acid-, and leucine-rich
RT   protein-1 (PELP1).";
RL   Mol. Endocrinol. 21:1847-1860(2007).
RN   [20]
RP   FUNCTION.
RX   PubMed=23932781; DOI=10.1016/j.molcel.2013.07.002;
RA   Lin R., Tao R., Gao X., Li T., Zhou X., Guan K.L., Xiong Y., Lei Q.Y.;
RT   "Acetylation stabilizes ATP-citrate lyase to promote lipid
RT   biosynthesis and tumor growth.";
RL   Mol. Cell 51:506-518(2013).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 493-658 IN COMPLEX WITH
RP   COENZYME A, AND ACTIVE SITE.
RX   PubMed=10393169; DOI=10.1093/emboj/18.13.3521;
RA   Clements A., Rojas J.R., Trievel R.C., Wang L., Berger S.L.,
RA   Marmorstein R.;
RT   "Crystal structure of the histone acetyltransferase domain of the
RT   human PCAF transcriptional regulator bound to coenzyme A.";
RL   EMBO J. 18:3521-3532(1999).
RN   [22]
RP   STRUCTURE BY NMR OF 715-832, AND MUTAGENESIS OF VAL-752; TYR-760;
RP   TYR-802 AND TYR-809.
RC   TISSUE=Liver;
RX   PubMed=10365964; DOI=10.1038/20974;
RA   Dhalluin C., Carlson J.E., Zeng L., He C., Aggarwal A.K., Zhou M.-M.;
RT   "Structure and ligand of a histone acetyltransferase bromodomain.";
RL   Nature 399:491-496(1999).
RN   [23]
RP   STRUCTURE BY NMR OF 719-832 IN COMPLEX WITH HIV-1 TAT.
RX   PubMed=11931765; DOI=10.1016/S1097-2765(02)00483-5;
RA   Mujtaba S., He Y., Zeng L., Farooq A., Carlson J.E., Ott M.,
RA   Verdin E., Zhou M.-M.;
RT   "Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF
RT   bromodomain.";
RL   Mol. Cell 9:575-586(2002).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 715-831.
RX   PubMed=22464331; DOI=10.1016/j.cell.2012.02.013;
RA   Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P.,
RA   Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T.,
RA   Gingras A.C., Arrowsmith C.H., Knapp S.;
RT   "Histone recognition and large-scale structural analysis of the human
RT   bromodomain family.";
RL   Cell 149:214-231(2012).
CC   -!- FUNCTION: Functions as a histone acetyltransferase (HAT) to
CC       promote transcriptional activation. Has significant histone
CC       acetyltransferase activity with core histones (H3 and H4), and
CC       also with nucleosome core particles. Also acetylates non-histone
CC       proteins, such as ACLY. Inhibits cell-cycle progression and
CC       counteracts the mitogenic activity of the adenoviral oncoprotein
CC       E1A. In case of HIV-1 infection, it is recruited by the viral
CC       protein Tat. Regulates Tat's transactivating activity and may help
CC       inducing chromatin remodeling of proviral genes. Acts as a
CC       circadian transcriptional coactivator which enhances the activity
CC       of the circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and
CC       CLOCK-ARNTL/BMAL1 heterodimers. {ECO:0000269|PubMed:10675335,
CC       ECO:0000269|PubMed:14645221, ECO:0000269|PubMed:23932781,
CC       ECO:0000269|PubMed:8684459, ECO:0000269|PubMed:9707565}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + [protein]-L-lysine = CoA +
CC       [protein]-N(6)-acetyl-L-lysine. {ECO:0000269|PubMed:8945521}.
CC   -!- SUBUNIT: Interacts with SIRT1. Interacts (unsumoylated form) with
CC       NR2C1; the interaction promotes transactivation activity (By
CC       similarity). Interacts with EP300, CREBBP and DDX17. Interacts
CC       with NCOA1 and NCOA3. Component of a large chromatin remodeling
CC       complex, at least composed of MYSM1, KAT2B/PCAF, RBM10 and
CC       KIF11/TRIP5. Interacts with NR2C2 (hypophosphorylated and
CC       unsumoylated form); the interaction promotes the transactivation
CC       activity of NR2C2. Binds to HTLV-1 Tax. Interacts with and
CC       acetylates HIV-1 Tat. Interacts with KLF1; the interaction does
CC       not acetylate KLF1 and there is no enhancement of its
CC       transactivational activity. Interacts with NFE4. Interacts with
CC       MECOM. Interacts with E2F1; the interaction acetylates E2F1
CC       augmenting its DNA-binding and transcriptional activity. Interacts
CC       with NPAS2, ARNTL/BMAL1 and CLOCK. Interacts with BCAS3. Interacts
CC       with CEBPB (PubMed:17301242). Interacts with NR4A3 (By
CC       similarity). {ECO:0000250, ECO:0000250|UniProtKB:Q9JHD1,
CC       ECO:0000269|PubMed:10675335, ECO:0000269|PubMed:10766811,
CC       ECO:0000269|PubMed:11568182, ECO:0000269|PubMed:11931765,
CC       ECO:0000269|PubMed:12486002, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:14767476, ECO:0000269|PubMed:15273251,
CC       ECO:0000269|PubMed:16887930, ECO:0000269|PubMed:17226766,
CC       ECO:0000269|PubMed:17301242, ECO:0000269|PubMed:17505058,
CC       ECO:0000269|PubMed:17707232, ECO:0000269|PubMed:8684459,
CC       ECO:0000269|PubMed:9296499, ECO:0000269|PubMed:9346901,
CC       ECO:0000269|PubMed:9707565}.
CC   -!- INTERACTION:
CC       P03255:- (xeno); NbExp=3; IntAct=EBI-477430, EBI-2603114;
CC       P03255-2:- (xeno); NbExp=3; IntAct=EBI-477430, EBI-6859460;
CC       O60566:BUB1B; NbExp=14; IntAct=EBI-477430, EBI-1001438;
CC       Q92793:CREBBP; NbExp=4; IntAct=EBI-477430, EBI-81215;
CC       P03129:E7 (xeno); NbExp=3; IntAct=EBI-477430, EBI-866453;
CC       Q96KQ7:EHMT2; NbExp=3; IntAct=EBI-477430, EBI-744366;
CC       Q09472:EP300; NbExp=2; IntAct=EBI-477430, EBI-447295;
CC       Q16665:HIF1A; NbExp=2; IntAct=EBI-477430, EBI-447269;
CC       P02299:His3:CG33854 (xeno); NbExp=2; IntAct=EBI-477430, EBI-522090;
CC       P84040:His4:CG33909 (xeno); NbExp=2; IntAct=EBI-477430, EBI-185028;
CC       Q96EB6:SIRT1; NbExp=3; IntAct=EBI-477430, EBI-1802965;
CC       Q8IXJ6:SIRT2; NbExp=4; IntAct=EBI-477430, EBI-477232;
CC       Q16594:TAF9; NbExp=3; IntAct=EBI-477430, EBI-712521;
CC       O88898-2:Tp63 (xeno); NbExp=3; IntAct=EBI-477430, EBI-2338228;
CC       Q15672:TWIST1; NbExp=2; IntAct=EBI-477430, EBI-1797287;
CC       P22415:USF1; NbExp=5; IntAct=EBI-477430, EBI-1054489;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed but most abundant in
CC       heart and skeletal muscle. {ECO:0000269|PubMed:8684459}.
CC   -!- DOMAIN: The bromodomain mediates binding to HIV-1 Tat.
CC   -!- SIMILARITY: Belongs to the acetyltransferase family. GCN5
CC       subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U57317; AAC50890.2; -; mRNA.
DR   EMBL; BC060823; AAH60823.1; -; mRNA.
DR   EMBL; BC070075; AAH70075.1; -; mRNA.
DR   CCDS; CCDS2634.1; -.
DR   PIR; S71788; S71788.
DR   RefSeq; NP_003875.3; NM_003884.4.
DR   UniGene; Hs.533055; -.
DR   PDB; 1CM0; X-ray; 2.30 A; A/B=493-658.
DR   PDB; 1JM4; NMR; -; B=719-832.
DR   PDB; 1N72; NMR; -; A=719-832.
DR   PDB; 1WUG; NMR; -; A=719-832.
DR   PDB; 1WUM; NMR; -; A=719-832.
DR   PDB; 1ZS5; NMR; -; A=719-832.
DR   PDB; 2RNW; NMR; -; A=719-832.
DR   PDB; 2RNX; NMR; -; A=719-832.
DR   PDB; 3GG3; X-ray; 2.25 A; A/B=715-831.
DR   PDB; 4NSQ; X-ray; 2.31 A; A/B/C/D=493-658.
DR   PDB; 5FDZ; X-ray; 2.40 A; A/B=715-831.
DR   PDB; 5FE0; X-ray; 2.30 A; A/B=715-831.
DR   PDB; 5FE1; X-ray; 2.22 A; A/B=715-831.
DR   PDB; 5FE2; X-ray; 2.25 A; A/B=715-831.
DR   PDB; 5FE3; X-ray; 2.12 A; A/B=715-831.
DR   PDB; 5FE4; X-ray; 2.15 A; A/B=715-831.
DR   PDB; 5FE5; X-ray; 2.12 A; A/B=715-831.
DR   PDB; 5FE6; X-ray; 1.77 A; A/B=715-831.
DR   PDB; 5FE7; X-ray; 2.08 A; A/B=715-831.
DR   PDB; 5FE8; X-ray; 2.10 A; A/B=715-831.
DR   PDB; 5FE9; X-ray; 2.35 A; A/B=715-831.
DR   PDB; 5LVQ; X-ray; 2.05 A; A/B=715-831.
DR   PDB; 5LVR; X-ray; 2.05 A; A/B=715-831.
DR   PDBsum; 1CM0; -.
DR   PDBsum; 1JM4; -.
DR   PDBsum; 1N72; -.
DR   PDBsum; 1WUG; -.
DR   PDBsum; 1WUM; -.
DR   PDBsum; 1ZS5; -.
DR   PDBsum; 2RNW; -.
DR   PDBsum; 2RNX; -.
DR   PDBsum; 3GG3; -.
DR   PDBsum; 4NSQ; -.
DR   PDBsum; 5FDZ; -.
DR   PDBsum; 5FE0; -.
DR   PDBsum; 5FE1; -.
DR   PDBsum; 5FE2; -.
DR   PDBsum; 5FE3; -.
DR   PDBsum; 5FE4; -.
DR   PDBsum; 5FE5; -.
DR   PDBsum; 5FE6; -.
DR   PDBsum; 5FE7; -.
DR   PDBsum; 5FE8; -.
DR   PDBsum; 5FE9; -.
DR   PDBsum; 5LVQ; -.
DR   PDBsum; 5LVR; -.
DR   ProteinModelPortal; Q92831; -.
DR   SMR; Q92831; -.
DR   BioGrid; 114375; 183.
DR   DIP; DIP-29778N; -.
DR   IntAct; Q92831; 37.
DR   MINT; MINT-150079; -.
DR   STRING; 9606.ENSP00000263754; -.
DR   BindingDB; Q92831; -.
DR   ChEMBL; CHEMBL5500; -.
DR   DrugBank; DB08186; (3E)-4-(1-METHYL-1H-INDOL-3-YL)BUT-3-EN-2-ONE.
DR   DrugBank; DB01992; Coenzyme A.
DR   DrugBank; DB08291; N-(3-AMINOPROPYL)-2-NITROBENZENAMINE.
DR   GuidetoPHARMACOLOGY; 2737; -.
DR   iPTMnet; Q92831; -.
DR   PhosphoSitePlus; Q92831; -.
DR   BioMuta; KAT2B; -.
DR   DMDM; 83287776; -.
DR   REPRODUCTION-2DPAGE; Q92831; -.
DR   MaxQB; Q92831; -.
DR   PaxDb; Q92831; -.
DR   PeptideAtlas; Q92831; -.
DR   PRIDE; Q92831; -.
DR   Ensembl; ENST00000263754; ENSP00000263754; ENSG00000114166.
DR   GeneID; 8850; -.
DR   KEGG; hsa:8850; -.
DR   UCSC; uc003cbq.4; human.
DR   CTD; 8850; -.
DR   DisGeNET; 8850; -.
DR   GeneCards; KAT2B; -.
DR   HGNC; HGNC:8638; KAT2B.
DR   HPA; CAB004526; -.
DR   HPA; HPA055839; -.
DR   MIM; 602303; gene.
DR   neXtProt; NX_Q92831; -.
DR   OpenTargets; ENSG00000114166; -.
DR   PharmGKB; PA162392705; -.
DR   eggNOG; KOG1472; Eukaryota.
DR   eggNOG; COG5076; LUCA.
DR   GeneTree; ENSGT00760000119099; -.
DR   HOGENOM; HOG000007151; -.
DR   InParanoid; Q92831; -.
DR   KO; K06062; -.
DR   OMA; HIAHLDN; -.
DR   OrthoDB; EOG091G03ZO; -.
DR   PhylomeDB; Q92831; -.
DR   TreeFam; TF105399; -.
DR   BRENDA; 2.3.1.48; 2681.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-5250924; B-WICH complex positively regulates rRNA expression.
DR   Reactome; R-HSA-5578768; Physiological factors.
DR   Reactome; R-HSA-5689901; Metalloprotease DUBs.
DR   Reactome; R-HSA-73762; RNA Polymerase I Transcription Initiation.
DR   SIGNOR; Q92831; -.
DR   ChiTaRS; KAT2B; human.
DR   EvolutionaryTrace; Q92831; -.
DR   GeneWiki; PCAF; -.
DR   GenomeRNAi; 8850; -.
DR   PRO; PR:Q92831; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000114166; -.
DR   CleanEx; HS_KAT2B; -.
DR   Genevisible; Q92831; HS.
DR   GO; GO:0031672; C:A band; IEA:Ensembl.
DR   GO; GO:0042641; C:actomyosin; IEA:Ensembl.
DR   GO; GO:0005671; C:Ada2/Gcn5/Ada3 transcription activator complex; IDA:BHF-UCL.
DR   GO; GO:0031674; C:I band; IEA:Ensembl.
DR   GO; GO:0000776; C:kinetochore; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0000125; C:PCAF complex; NAS:UniProtKB.
DR   GO; GO:0016407; F:acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0004861; F:cyclin-dependent protein serine/threonine kinase inhibitor activity; ISS:UniProtKB.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:UniProtKB.
DR   GO; GO:0004468; F:lysine N-acetyltransferase activity, acting on acetyl phosphate as donor; IDA:UniProtKB.
DR   GO; GO:0032403; F:protein complex binding; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISS:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0003712; F:transcription cofactor activity; IPI:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:ProtInc.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IDA:BHF-UCL.
DR   GO; GO:0006338; P:chromatin remodeling; IDA:UniProtKB.
DR   GO; GO:0043966; P:histone H3 acetylation; IDA:BHF-UCL.
DR   GO; GO:0043970; P:histone H3-K9 acetylation; IEA:Ensembl.
DR   GO; GO:0018393; P:internal peptidyl-lysine acetylation; IDA:UniProtKB.
DR   GO; GO:0018076; P:N-terminal peptidyl-lysine acetylation; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IEA:Ensembl.
DR   GO; GO:0007219; P:Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0018394; P:peptidyl-lysine acetylation; IDA:BHF-UCL.
DR   GO; GO:0045815; P:positive regulation of gene expression, epigenetic; TAS:Reactome.
DR   GO; GO:0035948; P:positive regulation of gluconeogenesis by positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0006473; P:protein acetylation; TAS:ProtInc.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0010835; P:regulation of protein ADP-ribosylation; IDA:BHF-UCL.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.920.10; -; 1.
DR   InterPro; IPR016181; Acyl_CoA_acyltransferase.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR016376; GCN5/PCAF.
DR   InterPro; IPR000182; GNAT_dom.
DR   InterPro; IPR009464; PCAF_N.
DR   Pfam; PF00583; Acetyltransf_1; 1.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF06466; PCAF_N; 1.
DR   PIRSF; PIRSF003048; Histone_acetylase_PCAF; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF55729; SSF55729; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS51186; GNAT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Acyltransferase; Biological rhythms;
KW   Bromodomain; Cell cycle; Complete proteome; Host-virus interaction;
KW   Nucleus; Polymorphism; Reference proteome; Transcription;
KW   Transcription regulation; Transferase.
FT   CHAIN         1    832       Histone acetyltransferase KAT2B.
FT                                /FTId=PRO_0000211208.
FT   DOMAIN      503    651       N-acetyltransferase.
FT                                {ECO:0000250|UniProtKB:Q92830,
FT                                ECO:0000255|PROSITE-ProRule:PRU00532}.
FT   DOMAIN      740    810       Bromo. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00035, ECO:0000305}.
FT   REGION      574    576       Acetyl-CoA binding.
FT                                {ECO:0000269|PubMed:10393169}.
FT   REGION      581    587       Acetyl-CoA binding.
FT                                {ECO:0000269|PubMed:10393169}.
FT   REGION      612    615       Acetyl-CoA binding.
FT                                {ECO:0000269|PubMed:10393169}.
FT   ACT_SITE    570    570       Proton donor/acceptor.
FT                                {ECO:0000303|PubMed:10393169}.
FT   VARIANT     386    386       N -> S (in dbSNP:rs17006625).
FT                                /FTId=VAR_034372.
FT   MUTAGEN     752    752       V->A: Reduced acetyl-lysine binding.
FT                                {ECO:0000269|PubMed:10365964}.
FT   MUTAGEN     760    760       Y->A: Reduced acetyl-lysine binding.
FT                                {ECO:0000269|PubMed:10365964}.
FT   MUTAGEN     802    802       Y->A: Reduced acetyl-lysine binding.
FT                                {ECO:0000269|PubMed:10365964}.
FT   MUTAGEN     809    809       Y->A: Complete loss of acetyl-lysine
FT                                binding. {ECO:0000269|PubMed:10365964}.
FT   CONFLICT    804    805       PP -> AA (in Ref. 1; AAC50890).
FT                                {ECO:0000305}.
FT   STRAND      494    499       {ECO:0000244|PDB:1CM0}.
FT   STRAND      503    505       {ECO:0000244|PDB:1CM0}.
FT   HELIX       509    525       {ECO:0000244|PDB:1CM0}.
FT   HELIX       531    538       {ECO:0000244|PDB:1CM0}.
FT   STRAND      543    550       {ECO:0000244|PDB:1CM0}.
FT   STRAND      553    563       {ECO:0000244|PDB:1CM0}.
FT   TURN        564    567       {ECO:0000244|PDB:1CM0}.
FT   STRAND      568    576       {ECO:0000244|PDB:1CM0}.
FT   HELIX       578    580       {ECO:0000244|PDB:1CM0}.
FT   STRAND      582    584       {ECO:0000244|PDB:1CM0}.
FT   HELIX       585    599       {ECO:0000244|PDB:1CM0}.
FT   STRAND      604    609       {ECO:0000244|PDB:1CM0}.
FT   TURN        611    613       {ECO:0000244|PDB:1CM0}.
FT   HELIX       614    618       {ECO:0000244|PDB:1CM0}.
FT   TURN        619    621       {ECO:0000244|PDB:1CM0}.
FT   STRAND      623    625       {ECO:0000244|PDB:1CM0}.
FT   HELIX       630    633       {ECO:0000244|PDB:1CM0}.
FT   STRAND      644    649       {ECO:0000244|PDB:1CM0}.
FT   HELIX       724    741       {ECO:0000244|PDB:5FE6}.
FT   STRAND      742    744       {ECO:0000244|PDB:1WUM}.
FT   HELIX       746    748       {ECO:0000244|PDB:5FE6}.
FT   TURN        754    756       {ECO:0000244|PDB:5FE6}.
FT   STRAND      757    759       {ECO:0000244|PDB:1ZS5}.
FT   HELIX       760    763       {ECO:0000244|PDB:5FE6}.
FT   STRAND      764    766       {ECO:0000244|PDB:1JM4}.
FT   HELIX       770    778       {ECO:0000244|PDB:5FE6}.
FT   HELIX       785    802       {ECO:0000244|PDB:5FE6}.
FT   STRAND      805    807       {ECO:0000244|PDB:1WUG}.
FT   HELIX       808    826       {ECO:0000244|PDB:5FE6}.
FT   STRAND      828    830       {ECO:0000244|PDB:1N72}.
SQ   SEQUENCE   832 AA;  93013 MW;  72F516E8BC00CC0C CRC64;
     MSEAGGAGPG GCGAGAGAGA GPGALPPQPA ALPPAPPQGS PCAAAAGGSG ACGPATAVAA
     AGTAEGPGGG GSARIAVKKA QLRSAPRAKK LEKLGVYSAC KAEESCKCNG WKNPNPSPTP
     PRADLQQIIV SLTESCRSCS HALAAHVSHL ENVSEEEMNR LLGIVLDVEY LFTCVHKEED
     ADTKQVYFYL FKLLRKSILQ RGKPVVEGSL EKKPPFEKPS IEQGVNNFVQ YKFSHLPAKE
     RQTIVELAKM FLNRINYWHL EAPSQRRLRS PNDDISGYKE NYTRWLCYCN VPQFCDSLPR
     YETTQVFGRT LLRSVFTVMR RQLLEQARQE KDKLPLEKRT LILTHFPKFL SMLEEEVYSQ
     NSPIWDQDFL SASSRTSQLG IQTVINPPPV AGTISYNSTS SSLEQPNAGS SSPACKASSG
     LEANPGEKRK MTDSHVLEEA KKPRVMGDIP MELINEVMST ITDPAAMLGP ETNFLSAHSA
     RDEAARLEER RGVIEFHVVG NSLNQKPNKK ILMWLVGLQN VFSHQLPRMP KEYITRLVFD
     PKHKTLALIK DGRVIGGICF RMFPSQGFTE IVFCAVTSNE QVKGYGTHLM NHLKEYHIKH
     DILNFLTYAD EYAIGYFKKQ GFSKEIKIPK TKYVGYIKDY EGATLMGCEL NPRIPYTEFS
     VIIKKQKEII KKLIERKQAQ IRKVYPGLSC FKDGVRQIPI ESIPGIRETG WKPSGKEKSK
     EPRDPDQLYS TLKSILQQVK SHQSAWPFME PVKRTEAPGY YEVIRFPMDL KTMSERLKNR
     YYVSKKLFMA DLQRVFTNCK EYNPPESEYY KCANILEKFF FSKIKEAGLI DK
//
